Molecular Formula | C20H17NO5 |
Molar Mass | 351.35 |
Density | 1.307±0.06 g/cm3(Predicted) |
Boling Point | 618.9±55.0 °C(Predicted) |
Solubility | DMSO: ≥ 29 mg/mL |
pKa | 3.45±0.36(Predicted) |
Storage Condition | -20℃ |
In vivo study | FT011 (100 mg/kg b.i.d., p.o., for 4 weeks) improves the cardiac function and and myocardial remodeling in myocardial infarction rats. Animal Model: Seventy male Sprague Dawley (SD) rats (weighing 200-250 g) Dosage: 100 mg/kg Administration: B.I.D., p.o. on day 7 after surgery, for 4 weeks Result: Increased ejection fraction, fraction shortening and preload recruitable stroke work. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.846 ml | 14.231 ml | 28.461 ml |
5 mM | 0.569 ml | 2.846 ml | 5.692 ml |
10 mM | 0.285 ml | 1.423 ml | 2.846 ml |
5 mM | 0.057 ml | 0.285 ml | 0.569 ml |
bioactivity | FT011 is an anti-fibrotic agent that reduces mRNA expression of collagen I and III and inhibits collagen synthesis. |
in vivo study | FT011 (100 mg/kg B.I. d., p.o., for 4 weeks) improvements the cardiac function and and myocardial reconstruction in myocardial infection rats. Animal Model: Seventy male Sprague Dawley (SD) rats (weighting 200-250g) Dosage: 100 mg/kg Administration: B.I.D., p.o. on day 7 after surgery, for 4 weeks Result: Increased ejection fraction, fraction shortening and preload recruitable stroke work. |
Animal Model: | Seventy male Sprague Dawley (SD) rats (weighing 200-250 g) |
Dosage: | 100 mg/kg |
Administration: | B.I.D., p.o. on day 7 after surgery, for 4 weeks |
Result: | Increased ejection fraction, fraction shortening and preload recruitable stroke work. |